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Background: Poverty undermines adherence to tuberculosis treatment. Economic support may both encourage
and enable patients to complete treatment. In South Africa, which carries a high burden of tuberculosis, such
support may improve the currently poor outcomes of patients on tuberculosis treatment. The aim of this study was
to test the feasibility and effectiveness of delivering economic support to patients with pulmonary tuberculosis in a
high-burden province of South Africa.
Methods: This was a pragmatic, unblinded, two-arm cluster-randomized controlled trial, where 20 public sector
clinics acted as clusters. Patients with pulmonary tuberculosis in intervention clinics (n = 2,107) were offered a
monthly voucher of ZAR120.00 (approximately US$15) until the completion of their treatment. Vouchers were
redeemed at local shops for foodstuffs. Patients in control clinics (n = 1,984) received usual tuberculosis care.
Results: Intention to treat analysis showed a small but non-significant improvement in treatment success rates in
intervention clinics (intervention 76.2%; control 70.7%; risk difference 5.6% (95% confidence interval: -1.2%, 12.3%),
P = 0.107). Low fidelity to the intervention meant that 36.2% of eligible patients did not receive a voucher at all,
32.3% received a voucher for between one and three months and 31.5% received a voucher for four to eight
months of treatment. There was a strong dose–response relationship between frequency of receipt of the voucher
and treatment success (P <0.001).
Conclusions: Our pragmatic trial has shown that, in the real world setting of public sector clinics in South Africa,
economic support to patients with tuberculosis does not significantly improve outcomes on treatment. However,
the low fidelity to the delivery of our voucher meant that a third of eligible patients did not receive it. Among
patients in intervention clinics who received the voucher at least once, treatment success rates were significantly
improved. Further operational research is needed to explore how best to ensure the consistent and appropriate
delivery of such support to those eligible to receive it.
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There is a large body of work, dating back over a century,
that emphasizes the close relationship between poverty
and tuberculosis (TB). Indeed, Robert Koch himself
described the disease as ‘the outcome of social misery’ [1].
Rene and Jean Dubois, who authored the seminal book
‘The White Plague: Tuberculosis, Man and Society’ called
TB ‘a social disease’ [2]. The prevalence of TB is higher in
poorer countries [3] and among poorer communities in
wealthy countries [4]. Indeed, in South Africa, a country
of profound income inequality [5], TB has been called a
‘barometer of poverty’ [6].
South Africa has one of the highest burdens of TB in
the world, which can be attributed, at least in part, to
conditions of poverty that favor its transmission [7]. In
addition, the high prevalence of HIV infection has
played a central role in increasing and maintaining the
high burden of TB in the country and may also be
responsible for undermining outcomes of patients on TB
treatment. The association between poverty and poor
adherence to anti-retroviral treatment [8,9] has profound
implications for the role of HIV in adherence to anti-TB
treatment and for outcomes of patients on that treatment.
At present, the outcomes of patients on TB treatment in
South Africa remain below the targets set by the World
Health Organization [10]. Although these outcomes have
improved over the last decade, the transmission rate of
TB has increased dramatically over this time and it has
been suggested that the current national strategy for TB
control, based on the Directly Observed Treatment
Strategy, is insufficient to control the epidemic [11].
The association between poverty and TB exists over
the entire course of the disease [12]. Although effective
treatment is available for drug-susceptible TB, and this is
provided free of charge in public sector clinics in South
Africa, there is a wealth of research that shows that the
effect of poverty on TB outcomes is due, at least in part, to
the costs of accessing and adhering to treatment [13-17].
In addition, the poor nutrition that often accompanies
poverty is not only a risk factor for the development
of TB [18-20], but undermines the outcomes of those
on TB treatment [21].
Although the association between poverty and TB is well
documented, there are very few programs which directly
address this relationship with economic interventions, and
even fewer research studies which evaluate them [12]. Such
research is difficult to do. Because of the scale on which
poverty occurs, its inherent complexity and the complex
relationship between different aspects of poverty and
disease, such studies may be difficult to design and
enormously costly to conduct. Addressing this point, the
Commission on the Socio-economic Determinants of
Health recently noted that, in spite of the growing body of
evidence to support action in this field, ‘there is a pressingneed to invest in a great deal more research, bringing
together different disciplines and areas of expertise, to
work out how social determinants create health inequity,
and how action on these determinants can produce better,
fairer health’” [22].
The call for research in the field of economic support
for improving TB outcomes has been echoed by several
authors who have conducted reviews on the effects on
health of results-based financing [23], conditional cash
transfers [24], economic incentives [25], and cash transfers
and microfinance [26]. A recent expert consultation on
Social Protection Interventions for Tuberculosis Control,
held at Chatham House in London in February 2012,
concluded that ‘a) despite the indirect evidence gathered
in a recent review from Boccia et al. (2011) [26], the
actual impact of social protection on TB indicators
(e.g. incidence, mortality, case finding, TB treatment
adherence) remains unknown; b) it is unclear how
social protection initiatives may be best integrated
with current TB control activities and which forms
of social protection are most likely to be successful,
depending on the objectives posed’ [27].
Our trial aimed to generate evidence on both of
these areas. It aimed to investigate the feasibility of
delivering a form of economic support to patients
with TB as an integrated part of the TB control program of
government-run clinics in South Africa, and to determine
whether such support was effective in improving the
outcomes of patients with TB in these clinics.
Methods
Study setting
This study was conducted in KwaZulu-Natal, one of
South Africa’s poorest and most populous provinces.
The province has the second highest population and
the second highest population density of the country,
including the highest number of children under the
age of one year [10]. The poverty rate amongst indi-
viduals in KwaZulu-Natal is the second highest in
the country, at 58.5%, and just over a quarter
(25.5%) of all poor individuals in the country live in
the province [28].
KwaZulu-Natal has the highest incidence of TB in
South Africa (1,142 per 100,000) as well as the highest
HIV prevalence rate nationally [10]. Probably because of
its high burden of HIV, the province has for several years
held the dubious honor of having the highest number of
patients with TB in the country (120,421 cases of all
types of TB in 2010) [10]. TB is the most important
cause of death in the province, causing 16.2% of all
deaths in 2009 [29].
At the request of a senior TB program manager during
the planning phase of the trial, our trial included one
urban district and one rural district.
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This was a pragmatic, unblinded two-arm cluster-
randomized controlled trial, using primary health care
clinics as clusters. Nested within the controlled trial was
a process evaluation, consisting of in-depth interviews
with research participants, and an assessment of the
effect of the voucher on patient household expenditures
(to be reported elsewhere).
A cluster-randomized design was chosen for this trial
because we felt it would be logistically easier for nurses
to deliver the intervention to all of their TB patients
(as opposed to a selected number) [30], and because
we hoped to avoid creating resentment among patients
who did not receive the intervention. In addition, to test
whether the administration of the intervention was feasible
as a routine part of the TB control program in South
Africa, this trial had a pragmatic nature [31]. Distinct from
an explanatory trial, which measures efficacy (‘the benefit a
treatment produces under ideal conditions’), a pragmatic
trial measures effectiveness (‘the benefit the treatment
produces in routine clinical practice’ [32]). Because trials
are seldom purely pragmatic or explanatory [33], their
position on the continuum between these can be described
by the relative orientation of the building blocks of
the trial. The ‘dimensions’ or ‘domains’ of the pragmatic-
explanatory continuum indicator summary (PRECIS) tool
are useful measures that give a holistic picture of the
general pragmatic or explanatory nature of the trial [34].
The orientation of the domains of this trial are presented
in Additional file 1.
Study setting and participants
Clinics
Public sector (government-funded) primary care
clinics were chosen for this study because these treat
the majority of patients with TB in South Africa.
These clinics are managed by professional nurses, and
staffed by nurses of all grades.
Clinics with cure rates of between 40% and 70% for the
year preceding the trial were eligible for inclusion in the
study. The upper limit was set because demonstrating a
clinically meaningful effect in clinics with cure rates
higher than 70% would have required a very large sample
size. The lower limit was set to reduce between-clinic
variability and to exclude clinics where poor service
provision and systemic weaknesses may have contributed
to poor cure rates. Nine clinics were excluded because
their cure rates were too high, and 66 were excluded
because their cure rates were too low. In addition, only
clinics seeing between 20 and 150 new patients with
smear-positive TB per year were eligible for inclusion. The
lower limit was set to meet the sample size requirements
of the trial, and the upper limit was set because
implementing the intervention in very large clinics wouldhave exceeded the limited budget of this trial. Fifty-five
clinics were excluded because they were too small, and 13
clinics because they were too big. These criteria meant
that, of a total of 209 public sector clinics providing TB
care in the districts chosen, only 26 (12%) were eligible for
inclusion in this trial (Figure 1).
Patients
All patients diagnosed with pulmonary, drug-sensitive
TB and attending intervention clinics within the period
1 July 2009 to 31 March 2010 were recruited into the
trial; however, only patients who started TB treatment
within this recruitment period were eligible for analysis.
Patients were followed up to the end of their treatment
(which is a maximum of six months in new cases and
eight months in re-treatment cases). Both adults and
children were included in the analysis because, as a
high-burden country, there are a significant number of
children receiving treatment for TB in South Africa.
Intervention
A voucher, valued at ZAR120 (approximately US$15) was
offered to patients by nurses every month on collection of
their treatment, to a maximum of eight months. A
voucher was preferred to cash by TB program managers
and other stakeholders with whom the study was
discussed, because it would be a security risk to hold large
sums of cash at clinics in KwaZulu-Natal; most patients at
public sector clinics would not have bank accounts, thus
making electronic transfers difficult; cash may be spent on
any items, and patients may have chosen to spend it on
unhealthy or damaging items such as cigarettes or alcohol;
and the expenditure of vouchers could be more easily
monitored.
The value of ZAR120 was chosen because it was
considered by TB program managers to be too small to
act as a perverse incentive for patients to remain ill, but
large enough to encourage patients to adhere to treatment.
The value of the voucher was lower than the food poverty
line of ZAR226 at the time of the study [35], and was about
a fifth of the value of the median per capita income
in KwaZulu-Natal around the time of the trial [36].
However, the amount was sufficient to purchase a
number of food stuffs commonly used in South African
households (Table 1). It was therefore hoped that the
voucher would allow households to increase expenditure
on food stuffs and so improve household food security
and the nutritional status of the index patient. It was also
hoped that the voucher would free up money spent on
food stuffs to meet other essential expenditure, such as
transport to the clinic.
The vouchers were redeemable at specific general
stores, chosen by the nurses at each participating clinic
on the basis of their proximity to the clinic and the
Clinics not included in the trial 
Urban district Rural district 
Total facilities  174  74 
Hospitals  30  9 
Results not available  25  15 
Cure rate too high 
and too small  0  8 
Cure rate too low  
and too small  49  3 
Cure rate too low  13  1 
Cure rate too high  1  0 
Clinic too small  24  31 
Clinic too big  11  2 
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 209  TB clinics assessed 
for eligibility 
 26  Clinics eligible  
(21 in urban area and 
5 in rural area)  
 20 Clusters  
randomised 
 20 Clinics randomly 
selected 
 10 Clusters assigned 
control (planned sample 
size: 900 patients) 
Outcome data collected  
on 2,107 TB patients  
post-randomisation  
(outcome data not  
available for 5 patients) 
Outcome data collected  
on 1,984 TB patients  
post-randomisation  
(outcome data not  
available for 13 patients) 
 10  Clusters received  
the intervention  
(planned sample  
size: 900 patients) Al
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Figure 1 Participant flow diagram.
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gram managers, patients were advised by clinic nurses to
spend the vouchers on healthy foodstuffs; however,
nurses did not monitor their expenditure and the stores
were asked to allow patients to purchase any goods up
to the value of the voucher.
Patients at control clinics received usual TB care.
Logistics of voucher delivery
Nurses at intervention clinics were supplied with vou-
cher books. Each voucher had a unique number and was
carbonized so that the information entered by the nurse
onto the top copy would appear on two other copies
below. The nurse entered the patient’s name, gender,
identity number and clinic number onto the voucher,
signed it and stamped the top copy with the clinic
stamp. A unique sticker was placed on each voucher,
without which it could not be redeemed, to minimize
the risk of fraudulent copies of vouchers being madeand used. The nurse gave the patient the top two vou-
cher copies and kept the final copy at the clinic. The pa-
tient took the two copies of the voucher to the
designated shop and exchanged these for goods. Both
copies of the voucher were retained by the shop. Every
four to six weeks, the principal investigator collected
one copy of the vouchers from the shop, and used these
to calculate the amount owed to the shop for goods pur-
chased. The shops kept one voucher copy for their own
records. The clinic copies were also collected to ensure
that the vouchers distributed tallied with the vouchers
redeemed.
Patients were asked to present their identity books or
clinic cards on redemption of the vouchers. The presen-
tation of an identity book was not mandatory as some
patients did not possess this document. Relatives or
friends were permitted to redeem vouchers on behalf of
very sick patients provided they presented the patients’
clinic cards along with the vouchers. Vouchers had to be
Table 1 Prices of selected food stuffs commonly used in
South African households, January 2010 (mid-way
through trial) [37]
Commodity Rural price in ZAR Urban price in ZAR
Full cream long life
milk (1 L)
10.28 9.72
Loaf of brown bread (700 g) 7.00 6.97
Loaf of white bread (700 g) 7.56 7.83
Maize meal (5 kg) 29.09 22.93
Margarine (500 g) 14.61 12.88
Peanut butter (400 g) 16.59 15.48
Rice (2 kg) 28.58 23.14
Sunflower oil (750 mL) 17.20 12.81
Ceylon/black tea (62.5 g) 7.06 7.02
White sugar (2.5 kg) 19.73 18.15
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not be exchanged for cash. No change was given by the
shops if the full amount was not spent, although patients
could supplement the vouchers with their own cash. The
till slips, indicating the purchases made and their prices,
were attached by cashiers to the redeemed vouchers and
collected with the vouchers by the principal investigator.
The data on patient purchases was analyzed and will be
reported elsewhere.
Support from study team for voucher delivery
At the outset of the trial, investigators showed the TB
nurses at each intervention clinic how to administer the
voucher. Each nurse was given a study information sheet
containing this information. If nurses were replaced,
outgoing nurses explained the process to new nurses
and this was reinforced by an additional visit from the
principal investigator. Nurses were able to telephone the
principal investigator at any time to discuss queries
about the voucher or its delivery. The investigators
visited each intervention clinic every four to six weeks to
collect the vouchers from the TB nurses and to discuss
any problems that might have arisen in the trial.
Similarly, managers of participating shops were shown
how the voucher was to be used at the outset of the
study. Managers were responsible for training cashiers
in the use of the voucher. Shops were visited by the
investigators every four to six weeks and at these
visits, any problems with the administration of the
voucher were discussed.
Ethics and consent
Ethical approval for the trial and its process evaluation
was received from the Committee for Human Research
at the University of Stellenbosch (N07/10/245). Permission
to conduct the trial was received from the KwaZulu-NatalProvincial Department of Health, the participating
District Offices, the Research Committee of the
eThekwini Municipality and the sisters in charge at
individual clinics. In addition, as ‘guardians’ of the
communities in which the trial took place, permission
to conduct the trial was received from the Health and
Safety Sub-Committee of elected City Councilors in
the urban district and from individual ward councilors
and traditional leaders of the isigodi (wards) where rural
clinics were situated. Although all participants in the main
trial were informed verbally and in writing of the study,
individual written consent from patients in intervention
clinics was not sought because the research was
considered to be very low risk, and because obtaining
informed consent from each individual might have
made the project unfeasible [30]. Waiver of written
informed consent from patients in intervention clinics
was approved by the Committee for Human Research
at the University of Stellenbosch before the trial started.
Individual written informed consent was obtained for all
participants in the process evaluation.
Registration
This trial is registered with Current Controlled Trials
(reference ISRCTN50689131), the South African Clinical
Trials Registry (reference DOH-27-0409-2791), the
Wellcome Trust Register of Clinical Trials (reference
083619) and the Pan African Clinical Trials Registry
(reference PACTR2010010001275437).
The trial protocol is available at the following web
address: http://www.hst.org.za/publications/study-protocol-
economic-incentives-improving-clinical-outcomes-patients-
tb-south-africa.
Outcomes
The primary outcome was TB treatment success, defined
as the sum of those patients cured and those completing
treatment. Secondary outcomes were default and treatment
failure rates. Data on other routine TB treatment outcomes
were also collected, although they were not in the original
protocol. The World Health Organization definitions for
these outcomes, which are used in South African clinics
and were used for the purposes of this study, are listed in
Additional file 2.
Outcomes were ascertained by participating clinics
using their usual procedures. In smear-positive patients,
this was done through sputum microscopy and culture
after six months of treatment in new patients and after
eight months of treatment in re-treatment patients. In
smear-negative patients, where initial diagnosis is based on
chest X-rays and clinical signs, cure cannot be determined
and treatment completion is the outcome used [38]. No
additional clinical investigations were performed for the
purposes of this study.
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adherence to treatment [14,39] were also collected. These
factors were age, gender, employment status, type of TB
and HIV status (determined by PCR or ELISA tests).
Clinic TB registers and individual patient files (held
at the clinics) and electronic TB registers (held at
participating district offices) were used as sources for
all these data. Patient files are completed by the consulting
nurse, and clinic registers are completed in many cases by
a clerk attached to the TB program in the clinic. The latter
are checked by the nurse or sister in charge of TB at the
clinic. In a few small clinics, where clerks are not available,
this record keeping is done by the nurse working in TB.
In this study, the clinic register was the primary source of
data. Patient files were used to fill in missing data for any
patients whose information in the clinic or electronic
registers was incomplete. Data obtained from clinic
registers were checked for accuracy by comparing the
outcomes obtained with those in a sample of individual
patient files. A 10% random sample of data from the total
trial population was checked. This was done by randomly
identifying a starting point on the trial database, and
retrieving every tenth patient file for those patients
from the clinic.
Statistical methods
Sample size
At the time of the study, there were a total of 144 clinics
in the urban and 65 clinics in the rural district providing
TB care. A list of those clinics meeting the inclusion criteria
was constituted. Twenty-one clinics in the urban and five
in the rural district were eligible for inclusion.
An intra-cluster correlation co-efficient of 0.03 was
calculated based on pre-trial data from the clinics. To
detect a 15% difference in treatment success rates
(which we felt would be the minimum difference
required to influence policy), based on a power of
90%, at a significance level of 5% (two-sided test) and
an average cluster size of 100, 18 clinics were necessary.
Twenty clinics were included in the sample to allow for
clinic drop out during the trial.
Randomization
The 20 study clinics were randomly selected from the
26 eligible clinics stratified by district. Sixteen study
clinics were selected in the urban and four in the
rural district. Within the two districts, the study
clinics were randomly assigned in a 1:1 ratio, using a
randomization list generated by the study statistician.
Clinics were allocated to intervention or control
groups by the study statistician and no changes were
made to this allocation. Staff members in all clinics
were aware that they were part of a trial to test the
effectiveness of a voucher.Clinics were enrolled by the principal investigator, and
participants within the clinics were enrolled by the
nurses in charge of TB care at each clinic.
Blinding
Because of the nature of the intervention, no blinding
was possible in this study. Data extractors were not
blinded as it was considered neither practical nor feasible
to conceal from them the intervention status of the clinics
from which they collected data.
Analysis
Analysis was by intention to treat and patient level data
was used for this purpose. For the binary study outcome
(treatment success achieved, not achieved) a generalized
linear model (GLM) was used to evaluate the intervention
effect with adjustment for the stratification of clinics at
randomization. The clustering effect of clinics was taken
into account through cluster robust variance estimation.
An exploratory analysis was also performed for the
primary outcome. In this analysis, the intervention
group was limited to participants who received at least
one voucher. The control group remained unchanged.
As a secondary analysis of the intention to treat
study population, a multiple regression model (GLM)
was done to investigate the impact of adjusting for
selected covariates on the estimated intervention effect.
The covariates included in this model were employment
status, whether the participant was a minor, whether the
TB type was smear positive or diagnosed clinically or
on X-ray, and gender. The model was evaluated for
interaction effects between the intervention and any
of the covariates.
A further secondary analysis was done to test for a
dose–response effect in the intervention arm. The study
outcome was evaluated against the number of months
the participant had received a voucher. The GLM approach
was used for this purpose [40].
Results
Participant flow
As seen in Figure 1, there was no loss of clinics in the
trial, and all eligible patients in each clinic were included
in the analysis. Loss to follow-up was small, with outcome
data unavailable on 0.2% of patients in intervention clinics
and 0.7% of patients in control clinics.
Recruitment
Recruitment of patients took place over eight months
(July 2009 to March 2010 inclusive). Patients who
started treatment during this period were followed
up to the end of their treatment. The trial ended on
30 September 2010, when the last recruited patients
completed their full course of treatment.
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A total of 4,091 patients were included in this study:
1,984 in the control arm and 2,107 in the intervention
arm. The number of patients enrolled by clinics varied
between 68 and 335.
The baseline characteristics of the two groups were
calculated and are presented in a comparative table
(Table 2).
Primary outcomes
Intention to treat analysis showed a small and non-
significant improvement in treatment success rates
in the group receiving the vouchers. The exploratory
analysis showed a larger and significant improvement in
treatment success rates in the intervention arm (Table 3).
There was greater variability in the outcomes of clinics
in the control arm compared with the intervention arm.
There were four clinics in the intervention arm with
treatment success rates of more than 80%, compared with
only one in the control arm, and three clinics in the control
arm with treatment success rates of less than 65%
compared with none in the intervention arm (Table 4).
Secondary outcomes
The treatment completion rates of patients in the
intervention arm were almost 10% higher than those
in the control arm; however, the cure rates of patients
in the intervention arm were slightly lower than those
in the control. Default, treatment interruption and
treatment failure rates were all lower in the intervention
arm (Table 5).
Ancillary analysis
The adjusted analysis (Table 6) reflects the intervention
effect in the presence of possible confounders (excluding
HIV status because the missing data for this variable
was too extensive). The intervention effect shown
(4.6%) is slightly smaller than in the unadjusted intentionTable 2 Baseline characteristics of trial cohorts
Total number of trial participants
Minimum number of participants per clinic
Maximum number of participants per clinic
Mean age of participants
Number (percentage) of male participants
Number (percentage) of participants in rural district
Number (percentage) of HIV-positive participants
Number of unemployed participants
Number of child participants (less than 13 years)
Number of smear-positive participants
Data on HIV status and employment were not available for all patients.to treat analysis (5.5%). Thus about 1% of the intervention
effect in the unadjusted analysis can be explained by
differences in the participants of the intervention and
control clinics.
Patients who were unemployed had significantly lower
treatment success rates than those who were employed.
Children under the age of 13 had significantly better
treatment success rates than those over 13 years,
women had better rates than men and patients with
smear-positive TB had significantly better treatment
success rates than those with smear-negative TB. No
significant interactions between any of these subgroups
were found (Table 6).
Adherence to the intervention
Of all 2,076 patients who were eligible to receive a
voucher for the six to eight months of their treatment,
813 (36.2%) did not receive a voucher at all, and 671
(32.3%) received a voucher for between one and three
months. The remainder received a voucher for four to
eight months of treatment. In many cases, nurses in
intervention clinics withheld vouchers from eligible
patients whom they felt were relatively better off financially
(process evaluation, to be reported elsewhere). This
preference for giving vouchers to patients who were
relatively more deprived is illustrated in an analysis of
eligible patients who received at least one voucher
compared to eligible patients who did not receive any
vouchers at all. In this group, there were significantly more
unemployed patients who received vouchers (P = 0.04),
whilst there were significantly fewer children who received
vouchers (P = 0.03) (Table 7). In addition, women were
more likely to receive vouchers than men (P = 0.026).
The effect of the vouchers was to increase treatment
success rates in unemployed patients from 67% in the
control arm to 71.7% in the intervention arm. In the
remaining patients the treatment success rate was 76.7%
in the control arm versus 82.8% in the intervention arm.Intervention clinics Control clinics
2,107 1,984
122 68
335 335
29 years 32 years
1,058 (50.2%) 1,069 (53.9%)
266 (12.6) 167 (8.4)
910 (68.0%) 1106 (73.0%)
1 081 (60.2%) 1 228 (66.2%)
386 (21.5%) 251 (13.5%)
903 (42.9%) 882 (44.5%)
Table 3 Primary outcome (treatment success) - intention to treat and exploratory analyses
Outcome Intervention group (%) Control group (%) Risk difference (%)
(95% confidence interval)a
P
Treatment success/Intention to treat analysis 1,606/2,107 (76.2) 1,402/1,984 (70.7) 5.6 (−1.2, 12.3) 0.107
Treatment success/Exploratory analysis 1,051/1,294 (81.2) 1,402/1,984 (70.7) 10.6 (3.7, 17.5) 0.003
The estimated intra-cluster correlation co-efficient for our study for the primary outcome was 0.033. This is very close to the intra-cluster correlation co-efficient
assumed in the sample size calculation (0.03). aEstimate from generalized linear model.
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vention boosted treatment completion rates in both
groups equally. Further analysis of unemployed patients
in the intervention group showed that eligible unemployed
patients who did not receive a voucher achieved a 60%
treatment success rate compared with 77.6% of the eligible
unemployed patients who did receive a voucher. There was
a strong dose–response effect (P <0.001) (Figure 2). The
treatment success rate of patients who did not receive any
vouchers was 68.3%, compared with a rate of more
than 90% in patients who received a voucher for five
months or more.Adverse events
The adverse events investigated in this study were
those related to the voucher, and not to the clinical
consequences of TB or its treatment. Specifically,
there were very few reports of patients spending the
vouchers on alcohol or cigarettes (assessment of
expenditure of vouchers, to be reported elsewhere),
‘leakage’ of vouchers, or coercion of staff by patients
to give them a voucher (process evaluation, to be
reported elsewhere). However, some staff were
concerned that the vouchers would create dependency
and incentivize non-adherence (process evaluation, to
be reported elsewhere). Also, some patients reported
in interviews that when relatives or friends had
redeemed vouchers on their behalf, the relatives had
not given them (the patients) the goods. Finally, thoseTable 4 Treatment success per clinic (intention to treat analy
Intervention clinics
Clinic Treatment success (%) Other TB outcome (%)
1 202 (80.16) 50 (19.84)
2 238 (78.55) 65 (21.45)
3 198 (68.99) 89 (31.01)
4 198 (68.99) 89 (31.01)
5 83 (68.03) 39 (31.97)
6 274 (81.79) 61 (18.21)
7 82 (66.67) 41 (33.33)
8 183 (81.33) 42 (18.67)
9 106 (83.46) 21 (16.54)
10 104 (74.82) 35 (25.18)patients who were not eligible to receive the vouchers
in intervention clinics (that is, those with extrapulmonary
TB) expressed varying degrees of anger about this, both to
clinic nurses and to the principal investigator (process
evaluation, to be reported elsewhere).Discussion
This was the first trial in Africa to investigate the effect
of economic support (a monthly voucher) on the
outcomes of patients on TB treatment. The trial
found a 5.6% improvement in treatment success rates
among patients who received the voucher, meaning
that for every 1,000 patients who received the voucher, an
additional 56 would have achieved treatment success. This
was lower than the 15% difference that the study was
powered to detect, which explains in part, the failure
of the trial to achieve a significant result. This failure
may be further explained by low fidelity to the intervention,
which is discussed further in the process evaluation
(to be reported elsewhere). The exploratory analysis,
which compared patients in intervention clinics who
had received at least one voucher to the control
group, showed significantly higher treatment success
rates in intervention compared to control clinics. A
powerful dose–response effect was demonstrated, with
patients who received vouchers more frequently being
more likely to complete treatment.
This trial aimed both to reward adherence behavior,
and to make adherence easier by ameliorating twosis)
Control clinics
Clinic Treatment success (%) Other TB outcome (%)
1 88 (89.80) 10 (10.20)
2 99 (52.66) 89 (47.34)
3 112 (58.03) 81 (41.97)
4 240 (71.64) 95 (28.36)
5 204 (73.81) 72 (26.09)
6 159 (68.24) 74 (31.76)
7 140 (72.16) 54 (27.84)
8 233 (77.67) 67 (22.33)
9 85 (85.86) 14 (14.14)
10 41 (60.29) 27 (39.71)
Table 5 Tuberculosis treatment outcomes for patients in
intervention and control clinics
Treatment outcome Intervention
group (%)
Control
group (%)
(n = 2,107) (n = 1,984)
Treatment completed 911 (43.2) 694 (35.0)
Cured 695 (33.0) 708 (35.7)
Defaulted 158 (7.5) 202 (10.2)
Treatment interrupted 0 (0.0) 15 (0.8)
Treatment failure 79 (3.8) 113 (5.7)
Multi-drug resistant TB 1 (0.1) 3 (0.2)
Died 151 (7.2) 137 (7.0)
Moved/transferred 107 (5.1) 99 (5.0)
No outcome data available 5 (0.2) 13 (0.7)
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http://www.trialsjournal.com/content/14/1/154features of poverty which are commonly associated
with TB: under-nutrition and limited access to health
care [12]. We hypothesized that the voucher (if used
for purchasing food) would improve patients’ food security
and release household funds for use elsewhere, such as for
transport to the clinic [14]. In 2008, 71% of the households
in KwaZulu-Natal lived on less than 40% of the median per
capita income of ZAR569.00 per month [36]. This suggests
that, although the value of the voucher was small relative
to the median per capita income at the time of the trial,
the voucher may nonetheless have facilitated a substantial
improvement in the food purchases of households.
The evidence for the efficacy or effectiveness of
economic support in improving the outcomes of patients
on TB treatment is slim. No conditional cash transfer
programs have been evaluated for their effect on TB
outcomes [24,26]. Although several randomized controlled
trials have tested the effects of economic incentives in the
context of TB ([25], only one has focused on patients with
active TB and only one (the same trial) was conducted in a
low-income country [41]. In that study, food supplements
to patients on TB treatment were found to have no effect
on cure rates. Other non-randomized studies investigating
the use of financial incentives in patients with active TB
have had varying results. One such project in China, whereTable 6 Regression model showing patient characteristics ass
Patient characteristic Number/Total for whom data for
this variable was available
Intervention group indicator 2107/4091
Unemployed (yes) 2309/3650
Child (yes) 637/3650
Smear-positive TB indicator 1785/3614
Female 1949/4076
Intercepta
aThe intercept represents the outcome in the control arm when all other covariatesboth patients and providers received cash incentives,
showed no impact on TB outcomes [42]. A second project
in Cambodia, where patients with TB received nutritional
supplementation and participated in a microfinance
program, showed improved cure rates in the intervention
group [43]. To our knowledge, no studies have tested the
impact of economic support on TB outcomes in Africa.
Social and economic interventions to strengthen TB
control are rare [12]. In South Africa, patients with
TB may be given food parcels when they collect their
treatment, and may also be eligible to receive a disability
grant. Disability grants, which are income replacement
grants, may be given to patients with TB if authorized by a
doctor. However, the determination of eligibility for these
grants is neither clear nor standardized and varies both
between and within provinces [44]. Neither the food
parcels nor the disability grants are conditional on
any outcomes or behaviors on the part of the patients.
Although data on receipt of food parcels and disability
grants are not recorded in the TB registers at South
African clinics, and were therefore not collected in this
trial, we expect that, due to randomization, the proportions
of patients receiving them would be the same across
intervention and control clinics.
In our study, the lack of a statistically significant effect
in the intention to treat analysis may be due in part to
the low fidelity to the intervention. It is likely that
eligible patients who did not receive any vouchers at all
were considered by nurses not to need them. Nurses in
the trial, who are used to rationing food supplements to
those patients whom they consider most needy, tended
to give vouchers out in the same way (process evaluation,
to be reported elsewhere). This is illustrated by the finding
that unemployed patients in intervention clinics were
more likely to receive vouchers than patients who
were employed (Table 7). Interestingly, eligible children
younger than 13 years were less likely to receive vouchers.
Although this seems surprising, it must be noted that the
majority of these children would have been in receipt of a
child support grant. One of the criteria reported by nurses
for not giving eligible patients vouchers was their receipt
of other forms of state grants (process evaluation, to beociated with treatment success (generalized linear model)
Adjusted risk difference 95% confidence interval P
0.046 −0.017, 0.109 0.153
−0.044 −0.092, 0.005 0.077
0.075 0.026, 0.124 0.003
0.04 0.008, 0.072 0.014
0.032 0.008, 0.056 0.014
0.718 0.643, 0.725 <0.001
= 0.
Table 7 Comparison of eligible patients who received vouchers with eligible patients who did not
Received at least one voucher Employed (%) Children (%) Pensioner (%) Student (%) Unemployed (%) Total (%)
No 117 (17.06) 178 12 2 377 686
(25.95) (1.75) (0.29) (54.96) (100.00)
Yes 172 202 16 6 691 1,087
(15.82) (18.58) (1.47) 0.55 (63.57) (100.00)
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http://www.trialsjournal.com/content/14/1/154reported elsewhere). Women, who in South Africa are
more likely to be poorer than men, were also more likely
to receive vouchers.
The analysis of treatment success rates in unemployed
patients shows that, within the intervention group,
unemployed patients who did receive a voucher achieved
better treatment success rates than those who did not.
However, reverse causality may be responsible for these
findings, as those who received vouchers may have been
those who attended the clinics more regularly. Thus
this finding should be interpreted with caution, and be
investigated in further research.
Further issues that may have contributed to the low
fidelity of our trial were the preference of some nurses
to give vouchers out in batches at month end, and the
logistical difficulties in ensuring that clinics did not run
out of vouchers (process evaluation, to be reported
elsewhere). That there was no quantification of the
impact of these issues on the fidelity to the trial protocol
is an important limitation of this trial. More rigorous
monitoring of our intervention may have improved68.3 
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detect a significant effect. However, an important aim
of this pragmatic trial was to assess the feasibility of
administering such vouchers under normal public sector
clinic conditions [31].
The exploratory analysis, which investigated the
effect of the vouchers in eligible patients who received at
least one, attempted to ‘estimate maximum achievable
treatment effect’ [33] in a particular subgroup of patients.
The patients in intervention clinics who received a
voucher at least once were systematically different
from the patients in intervention clinics who received
no vouchers, and so not only is the potential bias in
this analysis acknowledged, it can also to a certain extent
be described [31]. The patients who received the vouchers
were more likely to be unemployed, and therefore more
deprived, than those who did not, because of the nurses’
sense that they should give vouchers preferentially to
patients who needed them more (process evaluation, to be
reported elsewhere). This exploratory analysis suggests
that, in patients who received vouchers, they did have a83.7 
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intention to treat analysis is presented as the main and
most important finding of this trial, the exploratory analysis
is included because it adds possible explanatory detail
to the trial, and because it raises questions for further
research. Such research questions include:
 Would it be feasible to deliver these vouchers
(or a similar form of economic support) to poorer
patients only?
 How feasible would the means testing inherent in
such delivery be?
 Would such means testing be susceptible to
manipulation and corruption?
 How would other patients react to the targeting of
poorer patients for the receipt of a voucher?
 Would the effect demonstrated in the exploratory
analysis be replicated or increased if this voucher
were only given to more deprived patients?
The findings of the dose–response analysis support
those of the exploratory analysis by suggesting that these
vouchers have the potential to improve outcomes on
TB treatment. The fact that the subgroups of patients
who received the vouchers more frequently achieved
significantly better TB outcomes than those who
received it less frequently implies that higher fidelity
to the intervention may produce a significant benefit.
In addition, the dose–response analysis argues against
a perverse incentive effect of the voucher. If patients
did try to remain ill in order to continue receiving the
voucher, treatment success rates would have fallen with
frequency and duration of receipt. This is an important
finding, given the local and global concern about this
unintended consequence of conditional cash transfers,
economic incentives and results-based financing [23].
However, reverse causality cannot be ruled out here:
it is possible that patients who came to the clinic
more often of their own accord were more likely to
receive vouchers, and that it was their own motivation to
adhere that was responsible for their improved outcomes
on treatment, rather than the vouchers per se. Future
studies should investigate this phenomenon further.
Subgroup analysis showed that treatment success rates
were better in women, patients who were employed,
children under 13 years of age, and smear-positive
patients. Although such results are not found in all
settings, they do reflect the findings of many other studies
in Africa and elsewhere. In the African [45] and South
African contexts [46], women have been shown to have
better adherence to TB treatment. However, women in
some settings may need to seek permission to attend
clinics and may therefore have poorer adherence than
men [14]. In our study setting, employed patientsappeared to be better off financially than those who were
unemployed (assessment of patient poverty, to be reported
elsewhere). Although unemployed patients were more
likely to receive the voucher than those who were
employed, it is likely that the value of the voucher was too
small to overcome the barriers to adherence imposed
by unemployment and consequent poverty (process
evaluation, to be reported elsewhere). The poorer outcomes
of unemployed patients are reflected in the findings of
several studies in Africa and elsewhere, where low income
has been shown to be associated with poorer adherence to
TB treatment [14,45]. Further trials should investigate the
effect of greater values of economic support on TB
treatment outcomes, as well as possible confounders
that might affect this relationship. In our study, children
younger than 13 years had better outcomes on treatment
than those older than 13. Although in some contexts
adherence of children to TB treatment is low [47,48],
adherence of children in South Africa has been shown
to be high [49]. Finally, smear-positive TB was associated
in our study with better outcomes on treatment. A
possible explanation for this is that these patients are
less likely to be infected with HIV, which has been
identified as an independent risk factor for default
from TB treatment [45,46].
The omission of HIV from the analysis of patients’
responses to the vouchers, due to the lack of data on
participating patients’ HIV status and treatment, is an
important limitation of this trial. The co-infection rate
of TB and HIV in KwaZulu-Natal is high and both
the incidence and the geographical distribution of TB
in the country have been affected profoundly by HIV.
Importantly, under-nutrition, TB and HIV also seem
to act synergistically, thus creating the ‘perfect storm’
for epidemics in South Africa [50]. The high co-infection
rate of HIV and TB, and the effect of poverty on adherence
to treatment for both diseases, make it possible that patients
infected by HIV in this trial may have benefited even more
from these vouchers than those uninfected by the virus. It
is imperative that future research in this field investigate
whether and how co-infection with HIV modifies the
impact of economic support for patients on TB treatment.
Conclusions
Our pragmatic trial has shown that, in the real world
setting of public sector clinics in South Africa, economic
support to patients with TB does not significantly
improve outcomes on treatment. Our results suggest
that factors related to the administration of such support
may undermine its effectiveness. The low fidelity to the
delivery of this voucher meant that only a third of all
eligible patients received it for four months or more.
However, among patients in intervention clinics who
received the voucher at least once, treatment success
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http://www.trialsjournal.com/content/14/1/154rates were significantly improved. Further, the more
frequently the vouchers were received by patients, the
higher their probability of treatment success. Further
operational research is needed to explore how best to
ensure the consistent and appropriate delivery of such
support to those eligible to receive it, and whether,
under conditions of higher fidelity, the extent of the
benefit on treatment outcomes found in this study
can be increased.
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